NEW YORK – Horizon Discovery said on Tuesday that it has granted two commercial licenses for its CHOSource platform to biotechnology company Sanyou Biopharmaceuticals.
Sanyou will use Horizon's gene-edited Glutamine Synthetase knockout Chinese Hamster Ovary (CHO) K1 cell line for the development of preclinical antibody drug projects and to support the clinical development and commercialization of its customers' human biotherapeutic products. Sanyou will also offer CHOSource through its contract research services, Horizon added.
"Horizon's CHOSource facilitates the development of stable cell lines for the expression of antibodies and other recombinant proteins and is recognized in the industry and by regulators for high-yield manufacturing," Sanyou CEO David Lang said in a statement. "This robust platform will be key in enabling us to generate stable cell lines for the development of antibody drugs, diagnostic products, and cell therapy-related components, and allows us to provide a stronger one-stop solution to our clients with IND-ready projects through our contract research services and pipeline-enriching collaborations."
Financial and other terms of the deal were not disclosed.
"Sanyou is a leading biotechnology company with extensive experience in early-stage drug discovery, IND filing, and clinical trial management. The company has established an integrated innovative antibody drug R&D laboratory and we are pleased CHOSource has been selected to support its biotherapeutic pipeline and contract research services offering," added Jesús Zurdo, global head of Horizon's bioproduction business unit.
Horizon first signed a collaboration and license agreement with Mammoth Biosciences in January to develop a new generation of genetically engineered CHO cells for the production of biotherapeutics. The company is in the process of being acquired by PerkinElmer for $383 million.